Fund of NTI projects support will invest 305 million roubles in the charter capital of the company Personal Medication & Health Management (PM&HM). The project was approved within the framework of the NTI Healthnet roadmap.
PM&HM company developed a new delivery method for active pharmaceutical ingredient to the human organism to cure serious diseases. The development is based on the technology of creation of the nanoaerosol (particle size 50 to 300 nm) from the pharmaceutical products used to cure tuberculosis and oncological diseases existing on the market. The key difference of aerosol delivery is significant reduction of the side effects in the therapy. Such nanoaerosol can substitute intake of a number of severe drugs in chemotherapy programs.
In order to implement the technology, the company develops a special nanoaerosol inspirator and information service to manage treatment from the cloud platform and iOS and Android app. The software will not only identify every patient and accurately estimate the received dose, but it also will collect, process and store impersonal data of patient treatment.
The company has already carried out pre-clinical tests of the first antituberculosis drug and developed inspirator prototype that is now passing through the state registration procedure. The aim is to equip by 2025 not less than 30% of all medical institutions specializing in tuberculosis treatment with PM&HM devices, it will help to increase treatment efficiency of the severe and socially significant diseases. The scientists continue trials to use the technology to treat oncological, cardiovascular and other diseases.
In 2017, PM&HM company also received investments from IIDF in the amount of 120 million roubles.